Compare OABI & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OABI | BGY |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 515.6M |
| IPO Year | N/A | N/A |
| Metric | OABI | BGY |
|---|---|---|
| Price | $1.79 | $5.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.67 | N/A |
| AVG Volume (30 Days) | 283.3K | ★ 292.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.84 | N/A |
| Revenue Next Year | $40.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $4.67 |
| 52 Week High | $3.33 | $6.23 |
| Indicator | OABI | BGY |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 28.44 |
| Support Level | $1.68 | N/A |
| Resistance Level | $1.89 | $5.87 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 26.92 | 0.74 |
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.